-
Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia.
Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.
Fetal Diagn Ther 2013;33:149-55. -
Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J, Pinas A, Syngelaki A, Poon LC, Nicolaides KH.
J Matern Fetal Neonatal Med 2013;26:733-7. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Ferreira AF, Rezende JC, de Cassia C Oliveira R, Akolekar R, Nicolaides KH.
J Hum Hypertens 2013;27:261-4. -
Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:26-32. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis.
Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E.
Fetal Diagn Ther 2012;31:141-6. pdf -
Metabolomics and first-trimester prediction of early-onset preeclampsia.
Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K.
J Matern Fetal Neonatal Med 2012;25:1840-7. pdf -
Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis.
Roberge S, Giguère Y, Villa P, Nicolaides KH, Vainio M, Forest JC, von Dadelszen P, Vaiman D, Tapp S, Bujold E.
Am J Perinatol 2012;29:551-6. -
A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012;32:171-8. -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation.
Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012;31:42-8. -
Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation.
Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2012;31:87-93. -
Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population.
Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G.
Am J Obstet Gynecol 2012;207:374. -
A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks' gestation.
Maiz N, Wright D, Ferreira AF, Syngelaki A, Nicolaides KH.
Fetal Diagn Ther 2012;31:221-9. -
Lateral ventricles in aneuploidies at 11-13 weeks' gestation.
Loureiro T, Ushakov F, Maiz N, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 2012;40:282-7. -
Dilated fourth ventricle in fetuses with trisomy 18, trisomy 13 and triploidy at 11-13 weeks' gestation.
Loureiro T, Ferreira AF, Ushakov F, Montenegro N, Nicolaides KH.
Fetal Diagn Ther 2012;32:186-9. -
Comparison of two different sites of measurement for transabdominal uterine artery Doppler velocimetry at 11-13 weeks.
Lefebvre J, Demers S, Bujold E, Nicolaides KH, Girard M, Brassard N, Audibert F.
Ultrasound Obstet Gynecol 2012;40:288-92.